- Home
- LFLY vs ENVB Comparison
LFLY vs ENVB Comparison
Compare LFLY & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFLY
- ENVB
- Stock Information
- Founded
- LFLY 2010
- ENVB 1994
- Country
- LFLY United States
- ENVB United States
- Employees
- LFLY N/A
- ENVB N/A
- Industry
- LFLY Computer Software: Prepackaged Software
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- LFLY Technology
- ENVB Health Care
- Exchange
- LFLY Nasdaq
- ENVB Nasdaq
- Market Cap
- LFLY 4.0M
- ENVB 4.2M
- IPO Year
- LFLY N/A
- ENVB N/A
- Fundamental
- Price
- LFLY $1.54
- ENVB $0.37
- Analyst Decision
- LFLY Strong Buy
- ENVB Strong Buy
- Analyst Count
- LFLY 2
- ENVB 1
- Target Price
- LFLY $7.59
- ENVB $10.00
- AVG Volume (30 Days)
- LFLY 47.8K
- ENVB 346.2K
- Earning Date
- LFLY 11-07-2024
- ENVB 11-14-2024
- Dividend Yield
- LFLY N/A
- ENVB N/A
- EPS Growth
- LFLY N/A
- ENVB N/A
- EPS
- LFLY N/A
- ENVB N/A
- Revenue
- LFLY $35,868,000.00
- ENVB N/A
- Revenue This Year
- LFLY N/A
- ENVB N/A
- Revenue Next Year
- LFLY N/A
- ENVB N/A
- P/E Ratio
- LFLY N/A
- ENVB N/A
- Revenue Growth
- LFLY N/A
- ENVB N/A
- 52 Week Low
- LFLY $1.32
- ENVB $0.36
- 52 Week High
- LFLY $6.49
- ENVB $2.92
- Technical
- Relative Strength Index (RSI)
- LFLY 39.51
- ENVB 29.99
- Support Level
- LFLY $1.32
- ENVB $0.45
- Resistance Level
- LFLY $1.87
- ENVB $0.52
- Average True Range (ATR)
- LFLY 0.19
- ENVB 0.05
- MACD
- LFLY -0.01
- ENVB -0.01
- Stochastic Oscillator
- LFLY 32.74
- ENVB 4.44
About LFLY Leafly Holdings Inc.
Leafly Holdings Inc operates an online cannabis information resource platform. It offers cannabis retailers and brands subscription-based marketplace listings that provide its cannabis audience with information, reviews, menus, and ordering and delivery options through legal retailers.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.